Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities

作者：Philamer Calses, James J. Crawford, Jennie R. Lill, Anwesha Dey · 发表于：Trends in cancer · 年份：2019 · DOI：10.1016/j.trecan.2019.04.001 · 被引用次数：444 · 研究领域：Hippo pathway signaling and YAP/TAZ、Wnt/β-catenin signaling in development and cancer

The Hippo pathway remains a central focus in both basic and translational research and is a key modulator of developmental biology. Dysregulation of the pathway is associated with a plethora of human cancers and there are multiple efforts to target key components of the pathway for disease intervention. In this review, we briefly highlight the latest research advances around the core components of the Hippo pathway in cancer. More specifically, we discuss several genetic aberrations of these factors as mechanisms for the development of cancers, including genetic amplification, deletion, and gene fusions. Additionally, we highlight the role of the Hippo pathway in cancer therapy resistance and tumor immunogenicity. Last, we summarize the ongoing efforts to target the pathway in cancers.